

Monoclonal Antibody to HPV E7**Description**

Infection with specific types of HPV has been associated with an increased risk of developing cervical neoplasia. HPV types 16 and 18, two of the major high-risk types of HPV are strongly associated with cervical, vaginal, and vulvar malignancies. Early viral proteins E6 and E7 are key players in malignant transformation, as they inactivate Rb and p53 tumor suppressor and interact with other important factors of growth control. Integration of E6/E7 region into the human genome, in turn, results in a constitutive deregulated production of these oncoproteins, which drives the infected cell into a state of increased proliferation, thereby leading to malignant transformation.

Product Name

Mouse anti-HPV E7, cross react with HPV type 16, 18

Size: 100ug

Immunogen

Ni-NTA purified full-length recombinant HPV18 E7 expressed in E. Coli strain BL21 (DE3)

Applications

Western Blot, ELISA, IHC

Determine optimal working dilutions by investigator.

Storage: -20°C

Formulation

Antibodies are purified by protein G affinity chromatography

References

1. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. *Br J Cancer* 2004, 90:1407-1413
2. [Kraus I](#), [Molden T](#), [Holm R](#), [Lie AK](#), [Karlsen F](#), [Kristensen GB](#), [Skomedal H](#). *J Clin Microbiol* 2006, 44:1310-7

For Research Use Only